The new FX CorDiax is the most efficient dialyzer within the FX-class®. The core of the FX CorDiax is the Helixone® plus membrane, a targeted enhancement of the Helixone® membrane. Improved fiber design allows for better sieving of middle molecules such as β2-microglobulin (β2-m) while restricting the loss of vital albumin. As increased levels of β2-m are associated with higher mortality risk, the use of FX CorDiax High-Flux dialyzers or hemodiafilters facilitate best possible therapy outcomes.
New production technology combined with INLINE steam sterilization allows crucial enhancements of membrane porosity, reducing flow resistance and improving transport across the membrane.
|Optimized dialysate flow||The 3-dimensional microwave structure of the fiber ensures uniform radial dialysate flow around each fiber within the bundle by preventing fluid channeling, thereby enhancing clearance values and improving the overall performance of the dialyzer.|
|Better hemodynamics||The lateral blood-inlet port ensures more homogenous blood flow in the dialyzer header, preventing stagnation zones. The design essentially minimizes the risk of kinking, contributing to improved safety.|
|Enhanced convection||The more open structure of the Helixone®plus membrane support region serves to reduce diffusion resistance and increases convective filtration. This facilitates clearance of a broad range of uremic toxins, especially the middle molecules.|
|Kind to the environment||Advanced design goes beyond direct functionality, it also has to be easy on the environment. FX-class® dialyzers weigh half as much as dialyzers with polycarbonate housing, and at the same time use ecologically friendly plastics. This means a lower carbon-footprint as a result of fewer materials, less packaging, less fuel for transport and cleaner waste management.|
“… treating patients with online hemodiafiltration and FX CorDiax 60 instead of FX 60 dialyzers results in significantly increased reduction ratios of middle sized molecules without clinically relevant changes in albumin loss.”
1 Dellanna F. et al., (1996); Nephrology Dialysis Transplantation 11 (Suppl 2): 83-86.
2 Vega Vega O. et.al.; ERA-EDTA Congress 2012, Poster 457—FP.
3 Maduell et. al.; ERA-EDTA Congress 2013, May 20, Poster Number MP 390.
4 Bock A. et al., Journal of the American Society of Nephrology (2013); 24: SA-PO404.